Zhejiang Huahai Pharmaceutical (SHA:600521) obtained the approval of China's medical products administrator to conduct phase one trials for its HB0043 injection to treat hidradenitis suppurativa, according to a Friday filing with the Shanghai bourse.
Hidradenitis suppurativa is a long-term skin condition that causes skin abscesses and scarring.
Shares of the pharmaceutical company slipped 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments